Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome: A proactive pharmacovigilance program (SONAR) and comparative safety efforts of the Food and Drug Administration.

e18035 Background: In 2000, the Food and Drug Administration (FDA) approved Gemtuzumab ozogamycin (GO) for monotherapy treatment of patients age 60 and older with relapsed acute myeloid leukemia. A...